Vanguard Group
VYNE icon

Vanguard Group’s VYNE Therapeutics VYNE Stock Holding History

Vanguard Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$182K Buy
314,545
+124,162
+65% +$49.8K ﹤0.01% 4118
2025
Q3 		$63.8K Sell
190,383
-305,914
-62% -$200K ﹤0.01% 4269
2025
Q2 		$819K Buy
496,297
+20,647
+4% +$26.8K ﹤0.01% 3795
2025
Q1 		$752K Buy
475,650
+521
+0.1% +$1.28K ﹤0.01% 3789
2024
Q4 		$1.59M Buy
475,129
+31,611
+7% +$82.7K ﹤0.01% 3632
2024
Q3 		$834K Hold
443,518
– – ﹤0.01% 3825
2024
Q2 		$874K Buy
443,518
+373,885
+537% +$932K ﹤0.01% 3836
2024
Q1 		$214K Buy
69,633
+20,051
+40% +$43.2K ﹤0.01% 4168
2023
Q4 		$116K Buy
49,582
+4,687
+10% +$14.6K ﹤0.01% 4285
2023
Q3 		$181K Sell
44,895
-1
-0% -$4 ﹤0.01% 4270
2023
Q2 		$184K Buy
44,896
+7,038
+19% +$37.5K ﹤0.01% 4323
2023
Q1 		$117K Sell
37,858
-53,842
-59% -$193K ﹤0.01% 4390
2022
Q4 		$248K Buy
91,700
+62
+0.1% +$248 ﹤0.01% 4268
2022
Q3 		$368K Sell
91,638
-8,391
-8% -$53.7K ﹤0.01% 4297
2022
Q2 		$700K Buy
100,029
+17,811
+22% +$149K ﹤0.01% 4198
2022
Q1 		$962K Sell
82,218
-42,573
-34% -$506K ﹤0.01% 4219
2021
Q4 		$2.29M Sell
124,791
-10,566
-8% -$227K ﹤0.01% 3989
2021
Q3 		$3.39M Hold
135,357
– – ﹤0.01% 3867
2021
Q2 		$8.55M Sell
135,357
-2,935
-2% -$232K ﹤0.01% 3291
2021
Q1 		$17M Buy
138,292
+33,534
+32% +$4.86M ﹤0.01% 2864
2020
Q4 		$11.9M Buy
104,758
+6,529
+7% +$821K ﹤0.01% 2903
2020
Q3 		$11.7M Buy
98,229
+999
+1% +$117K ﹤0.01% 2708
2020
Q2 		$12.1M Buy
97,230
+83,088
+588% +$11.3M ﹤0.01% 2669
2020
Q1 		$2.73M Buy
14,142
+6,777
+92% +$2.13M ﹤0.01% 3214
2019
Q4 		$2.46M Sell
7,365
-22
-0.3% -$7.33K ﹤0.01% 3389
2019
Q3 		$2.38M Sell
7,387
-384
-5% -$124K ﹤0.01% 3392
2019
Q2 		$3.35M Buy
7,771
+320
+4% +$158K ﹤0.01% 3306
2019
Q1 		$4.21M Buy
7,451
+5,253
+239% +$2.52M ﹤0.01% 3197
2018
Q4 		$653K Sell
2,198
-4,176
-66% -$1.87M ﹤0.01% 3675
2018
Q3 		$4.52M Buy
6,374
+2,739
+75% +$1.69M ﹤0.01% 3275
2018
Q2 		$2.13M Buy
3,635
+820
+29% +$637K ﹤0.01% 3479
2018
Q1 		$7.62M Buy
+2,815
New +$6.85M ﹤0.01% 2959

Other funds holding VYNE

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group's VYNE Position: Q4 2025 in Review

Vanguard Group increased its VYNE Therapeutics (VYNE) stake by 65% in Q4 2025, buying an estimated $49.8K and bringing the position to 314,545 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #4118.

Vanguard Group first reported a position in VYNE in Q1 2018 and has held it in 32 quarters since. The position peaked at $17M in Q1 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q4 2025.

  • Vanguard Group held 314,545 shares of VYNE Therapeutics worth $182K as of Q4 2025.
  • Vanguard Group bought 124,162 VYNE Therapeutics shares in Q4 2025, an estimated $49.8K.
  • VYNE Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4118 holding.
  • Vanguard Group first reported a position in VYNE Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Vanguard Group's VYNE Therapeutics position peaked at $17M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.